Escitalopram Pill for Melancholia

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Melancholia+3 More
Escitalopram Pill - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for depression in people 60 and older. It will involve 4 MRIs to track changes in brain function.

Eligible Conditions
  • Melancholia
  • Major Depressive Disorder (MDD)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: Weeks 1-12

Baseline
Age of Onset
Antidepressant Treatment History Questionnaire (ATHF)
Duration of Illness
Baseline and Week 12
Neuropsychological evaluations
Week 12
Hamilton Anxiety Rating Scale (HARS)
Response Styles Questionnaire- Rumination (RSQ-Rumination)
Week 12
Change in Montgomery Asberg Depression Rating Scale Score
Week 12
Change in Functional Connectivity
Weeks 1-12
Medication Plasma Levels

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

3 Treatment Groups

Escitalopram Pill
1 of 3
Levomilnacipran Pill
1 of 3
Placebo
1 of 3

Active Control

Non-Treatment Group

140 Total Participants · 3 Treatment Groups

Primary Treatment: Escitalopram Pill · Has Placebo Group · Phase 4

Escitalopram Pill
Drug
ActiveComparator Group · 1 Intervention: Escitalopram Pill · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Levomilnacipran Pill
Drug
ActiveComparator Group · 1 Intervention: Levomilnacipran Pill · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: weeks 1-12

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,525 Previous Clinical Trials
1,815,347 Total Patients Enrolled
Howard AizensteinLead Sponsor
Weill Cornell Institute of Geriatric PsychiatryUNKNOWN
Howard J Aizenstein, MD, Ph.D.Principal InvestigatorCharles F. Reynolds III and Ellen G. Detlefsen Endowed Chair in Geriatric Psychiatry and Associate Professor of Bioengineering and Clinical and Translational Science
Carmen Andreescu, MDPrincipal InvestigatorAssistant Professor of Psychiatry
1 Previous Clinical Trials
24 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
: The Modified Mini-Mental State (3MS) score is greater than or equal to 84.
The person has a mood disorder that involves a depressed mood most of the day, nearly every day, for at least two years.
A score of 13 or above on the MoCA-BLIND test is considered a sign of severe impairment.
People who are 60 years old or older are eligible to vote.
The person has a score of 12 or more on the Montgomery-Asberg Depression Rating Scale.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: November 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References